Picture a stability study that went quietly wrong. A peptide solution sits on a bench for two weeks, and a reverse-phase HPLC run afterward shows the main peak has shrunk and a cluster of new, earlier-eluting peaks has appeared. A colleague runs the same aliquot through a commercial ELISA kit and gets a concentration within a few percent of the day-zero value. Both instruments worked correctly. They simply measured different things, and the gap between those two numbers is the most important thing to understand before an immunoassay result goes into a lab notebook.
What an ELISA actually counts
An enzyme-linked immunosorbent assay converts antibody binding into a colored, fluorescent or luminescent signal. The signal rises or falls with the amount of material the antibodies can grab. That is not the same quantity as the amount of intact, full-length peptide in the tube.
Antibodies recognize epitopes: short stretches of sequence, often only a handful of residues, sometimes with a particular local shape. Any molecule presenting that stretch is fair game. In practice that means three families of look-alikes can inflate a reading:
- Degradation products that still carry the epitope. A peptide clipped at the far end from the recognized region looks untouched to the antibody.
- Close analogs that differ by a single substitution, a D-residue or an end-group change. Unless the antibody happens to bind across the altered position, it cannot tell them apart.
- Truncated sequences left over from synthesis. A deletion or truncation impurity of the kind described in our article on peptide synthesis impurities can be fully immunoreactive.
The honest label for an ELISA result is therefore “immunoreactive material,” not “peptide concentration.” For questions where degradation matters, such as stability work, a separation technique that resolves each species individually is the appropriate tool.
Where the antibody’s blind spots come from
Peptides of a few dozen residues or fewer are usually too small to provoke a strong immune response by themselves. Antibody production therefore starts by coupling the peptide to a large carrier protein, typically through a reactive group at one terminus or through an added cysteine. The coupled end is partly buried against the carrier, so the resulting antibodies tend to learn the exposed end and the middle.
That history has a practical consequence. If the peptide was attached through its C-terminus, antibodies raised against it may be largely indifferent to what happens at that end: whether it is amidated or a free acid, or whether a residue has been lost there. Two compounds that differ only in that region can give essentially identical signals. When evaluating a kit, it is worth asking how the immunogen was built, because that often predicts what the assay cannot see.
Sandwich versus competitive formats
Two plate layouts dominate peptide work, and they behave differently enough that the format should always be recorded alongside the result.
| Feature | Sandwich (two-site) | Competitive |
|---|---|---|
| How it works | A capture antibody on the plate binds the analyte; a labeled detection antibody binds a second site | Sample analyte and a labeled version of it compete for a limited amount of antibody |
| Signal direction | Rises with concentration | Falls with concentration |
| Needs two separate epitopes? | Yes | No |
| Fit for short peptides | Often poor, because two antibodies may not fit on a small molecule at once | Usually the practical choice |
| Typical specificity | Higher, since two sites must match | Lower, since one site decides binding |
The sandwich design earns its specificity by demanding two matches. For a short peptide that requirement can be impossible to satisfy, which is why many small-peptide kits are competitive and why their cross-reactivity data deserve extra scrutiny.
The standard curve carries hidden assumptions
An ELISA does not measure concentration directly. It compares sample signal with a curve built from standards of assumed concentration, so every reported value inherits the accuracy of those standards.
This is where content questions come back in. A lyophilized peptide weighed out as a standard is not pure peptide by mass; it also contains counter-ion and residual water, a point explained in peptide purity vs net peptide content. If the standard’s stated concentration assumes the whole weighed mass is peptide, the standard is overstated, and every unknown read against it comes out low by the same factor. The assay can be precise and still systematically wrong.
The shape of the curve matters too. Competitive curves in particular are sigmoidal: steep in the middle and nearly flat at both ends. Samples that land near the top or bottom plateau have large uncertainty, and anything above the highest standard is an extrapolation, not a measurement. Dilute and rerun rather than trusting a value off the end of the curve.
Matrix effects and how to test for them
Standards are usually prepared in a clean diluent. Real samples rarely are. Detergents, carrier proteins, salts, organic solvent carried over from a stock, or components of cell culture medium can change antibody binding, raise background or block the plate surface. Two routine checks expose most of these problems:
- Spike-and-yield. Add a known amount of analyte to the actual sample matrix and measure how much the assay reports. A result far from the amount added points to interference.
- Dilutional linearity. Run a sample at several dilutions. After correcting for the dilution factor, the values should agree. A trend with dilution means something in the matrix is changing the response.
Both checks should be run in the matrix the samples actually occupy, not in assay buffer, or they prove nothing about the real measurement.
Two ways an ELISA misleads without warning
The first is the hook effect, sometimes called the prozone effect. In a one-step sandwich format, a very high analyte concentration saturates both the capture and detection antibodies separately, so fewer complete sandwiches form and the signal drops. A grossly concentrated sample can therefore read deceptively low. Running every unknown at two or more dilutions catches this; a single dilution cannot.
The second happens before the plate. Peptides adsorb to plastic and glass surfaces, and losses during serial dilution, transfer and holding in ordinary labware are common at the low concentrations ELISA is designed for. The assay then faithfully measures what remained, which may be well below what was intended.
Where ELISA earns its place
None of this makes immunoassay a poor technique. It reaches concentrations far below what UV-based chromatography can quantify, tolerates complex samples, and processes dozens of wells in parallel. For locating a known analyte at low concentration in a messy background, few methods are as practical.
It is the wrong tool for establishing identity, assigning purity or separating intact material from its breakdown products. Those jobs belong to reverse-phase HPLC and mass spectrometry. Battle Born’s own published product results come from independent reverse-phase HPLC for exactly that reason: the question there is purity, and a separation answers it.
Questions
Can an ELISA result replace an HPLC purity figure?
No. An immunoassay reports how much material binds its antibodies. It cannot distinguish the intact peptide from fragments or analogs that share the epitope, so it says nothing reliable about purity.
Why does a degraded sample sometimes still read at full strength?
Because the breakdown products may keep the region the antibodies recognize. The signal counts them along with any intact peptide, so the loss is invisible to the assay.
What should be documented with every ELISA result?
The kit and format, the standard used and how its concentration was assigned, any cross-reactivity data, spike-and-yield and dilutional linearity in the real matrix, and whether each sample fell inside the calibrated range.
Is a competitive assay less trustworthy than a sandwich assay?
Not inherently, but it depends on a single binding event, so its specificity rests entirely on one antibody. Its cross-reactivity profile needs closer reading.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.